Evidence map›Paper›PMID 30628843›Full record

ArticleThe journal of histochemistry and cytochemistry : official journal of the Histochemistry Society2019

Selecting an Optimal Positive IHC Control for Verifying Antigen Retrieval.

Seshi R Sompuram, Kodela Vani, Anika K Schaedle, Anuradha Balasubramanian, Steven A Bogen

Abstract read
In one paragraph

Article in The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. A Consortium for Analytic Standardization in Immunohistochemistry.Archives of pathology & laboratory medicine · 2022
    Review
  6. Article
  7. A Root Cause Analysis Into the High Error Rate in Clinical Immunohistochemistry.Applied immunohistochemistry & molecular morphology : AIMM
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Seshi R SompuramMedical Discovery Partners LLC, Boston, Massachusetts.
Kodela VaniMedical Discovery Partners LLC, Boston, Massachusetts.
Anika K SchaedleMedical Discovery Partners LLC, Boston, Massachusetts.
Anuradha BalasubramanianMedical Discovery Partners LLC, Boston, Massachusetts.
Steven A BogenMedical Discovery Partners LLC, Boston, Massachusetts.

Funding

Tufts Clinical and Translational Research InstituteUL1TR001064 · NCATS · TUFTS UNIVERSITY BOSTON · PI SELKER, HARRY P. · 2013 to 2017
$26.4M
Regulatory Validation of Standardized Clinical Laboratory Immunohistochemistry ControlsR44CA213476 · NCI · BOSTON CELL STANDARDS INC · PI BOGEN, STEVEN A · 2017 to 2018
$1.5M
Regulatory Validation of Standardized Clinical Immunohistochemistry ControlsR44CA183203 · NCI · BOSTON CELL STANDARDS INC · PI BOGEN, STEVEN A · 2014 to 2016
$1.4M
NCATS NIH HHS UL1 TR001064NCI NIH HHS R44 CA183203NCI NIH HHS R44 CA213476
6 · The paper itself

Abstract

Positive immunohistochemistry (IHC) controls are intended to detect problems in both immunostaining and heat-induced epitope retrieval (HIER). However, it is not known what features in a control are important for verifying HIER. Contrary to expectation, the fact that a tissue is formalin-fixed does not necessarily render it suitable in verifying proper HIER. Some tissue controls, for some immunostains, strongly stain even without HIER. Consequently, the control may verify the immunostain but provide little or no information regarding the HIER step. To sort this out, we used formalin-fixed peptide epitopes, a model that provides for precise definition of analyte concentration, epitope composition, and degree of fixation. Our data demonstrate that formalin fixation generates a variable level of protein epitope masking, depending on the epitope recognized by the primary antibody. Some epitopes are highly masked while others hardly at all. Furthermore, the ability of amino acids in the epitope to react with formaldehyde can, at least in part, account for this variability. Most important, we demonstrate the importance of selecting a positive control with a low or intermediate analyte concentration (relative to the immunostain's analytic sensitivity). High analyte concentrations can be insensitive in verifying the HIER step.

Indexed as

AntigensEpitopesErb-b2 Receptor Tyrosine KinasesFormaldehydeHumansImmunohistochemistryParaffin EmbeddingPeptidesReceptors, EstrogenReceptors, ProgesteroneTissue FixationAntigensEpitopesERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesFormaldehydePeptidesReceptors, EstrogenReceptors, Progesteroneantigen retrievalcontrolepitopeformaldehydeIHCimmunohistochemistryimmunostainpeptide

Identifiers

PMID30628843
PMCPMC6437345

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.